Therapy partial responder adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From October 2011 to June 2026, FDA received 14,864 adverse event reports that record the MedDRA preferred term Therapy partial responder. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 2,910 reports in the 12 months to June 2026 and 2,764 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 260 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 2,910 (0.2%) record this term. Reports for female patients were 40.5% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 144 drug pages with 50 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Therapy partial responder name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		94
Actemra	Interleukin-6 receptor antagonist	175
Adalimumab	Tumor necrosis factor blocker	240
Aimovig		61
Arava	Antirheumatic agent	65
Aripiprazole	Atypical antipsychotic	133
Atezolizumab	Programmed death Receptor-1 blocking antibody	207
Azathioprine	Purine antimetabolite	225
Bendamustine		165
Bendamustine hydrochloride	Alkylating drug	93
Bevacizumab	Vascular endothelial growth factor inhibitor	840
Bleomycin	Cytoprotective agent	59
Bortezomib	Proteasome inhibitor	395
Capecitabine	Nucleoside metabolic inhibitor	371
Carbamazepine	Mood stabilizer	81
Carboplatin	Platinum-based drug	1,268
Carfilzomib	Proteasome inhibitor	482
Carmustine	Alkylating drug	54
Cetuximab	Epidermal growth factor receptor antagonist	51
Cisplatin	Platinum-based drug	724
Clobazam	Benzodiazepine	58
Clonazepam	Benzodiazepine	97
Clozapine	Atypical antipsychotic	114
Colchicine	Alkaloid	54
Cosentyx	Interleukin-17A antagonist	81
Cyclophosphamide	Alkylating drug	1,376
Cyclosporine	Calcineurin inhibitor immunosuppressant	321
Cytarabine	Nucleoside metabolic inhibitor	315
Dacarbazine	Alkylating drug	65
Dapsone	Sulfone	50
Daratumumab	CD38-directed cytolytic antibody	177
Denosumab	RANK ligand inhibitor	50
Dexamethasone	Corticosteroid	1,266
Docetaxel	Microtubule inhibitor	231
Doxorubicin	Anthracycline topoisomerase inhibitor	700
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	134
Doxycycline	Tetracycline-class drug	75
Durezol		97
Enbrel	Tumor necrosis factor blocker	96
Enfortumab vedotin		121
Entyvio	Integrin receptor antagonist	82
Epirubicin		105
Erlotinib	Kinase inhibitor	68
Etanercept	Tumor necrosis factor blocker	66
Etoposide	Topoisomerase inhibitor	712
Everolimus	Kinase inhibitor	59
Feiba		72
Filgrastim	Leukocyte growth factor	185
Fludarabine	Nucleoside metabolic inhibitor	107
Fluorouracil	Nucleoside metabolic inhibitor	513
Fulvestrant	Estrogen receptor antagonist	74
Gabapentin	Anti-epileptic agent	209
Gemcitabine	Nucleoside metabolic inhibitor	398
Haloperidol	Typical antipsychotic	64
Human immunoglobulin g	Human immunoglobulin G	76
Humira		104
Hydroxychloroquine	Antimalarial	167
Ibrutinib (form s4)	Kinase inhibitor	95
Ibuprofen	Nonsteroidal anti-inflammatory drug	108
Ifosfamide	Alkylating drug	248
Imatinib	Kinase inhibitor	100
Infliximab	Tumor necrosis factor blocker	168
Irinotecan		288
Ixazomib	Proteasome inhibitor	98
Keytruda	Programmed death Receptor-1 blocking antibody	900
Kyprolis	Proteasome inhibitor	61
Lacosamide		50
Lamotrigine	Anti-epileptic agent	96
Lenalidomide	Thalidomide analog	479
Lenvatinib	Kinase inhibitor	90
Lenvatinib mesylate		75
Lenvima	Kinase inhibitor	139
Letrozole	Aromatase inhibitor	149
Leucovorin		260
Leucovorin calcium	Folate analog	108
Levetiracetam		146
Lidocaine	Amide local anesthetic	90
Lorazepam	Benzodiazepine	98
Melphalan	Alkylating drug	183
Methotrexate	Folate analog metabolic inhibitor	794
Methotrexate sodium	Folate analog metabolic inhibitor	50
Methylprednisolone	Corticosteroid	337
Mycophenolate mofetil	Antimetabolite immunosuppressant	499
Nivolumab	Programmed death Receptor-1 blocking antibody	97
Olanzapine	Atypical antipsychotic	190
Omalizumab	Anti-IgE	134
Orencia	Selective T cell costimulation modulator	51
Orenitram	Prostacycline vasodilator	104
Otezla	Phosphodiesterase 4 inhibitor	161
Oxaliplatin	Platinum-based drug	579
Oxervate		113
Paclitaxel	Microtubule inhibitor	710
Panitumumab	Epidermal growth factor receptor antagonist	206
Pegfilgrastim	Leukocyte growth factor	57
Pembrolizumab	Programmed death Receptor-1 blocking antibody	784
Pemetrexed	Folate analog metabolic inhibitor	353
Pertuzumab	HER2/neu receptor antagonist	100
Pomalidomide	Thalidomide analog	146
Prednisolone	Corticosteroid	562
Prednisone	Corticosteroid	1,278
Pregabalin		104
Procytox		70
Quetiapine	Atypical antipsychotic	63
Quetiapine fumarate	Atypical antipsychotic	62
Remicade	Tumor necrosis factor blocker	64
Remodulin	Prostacycline vasodilator	139
Revlimid	Thalidomide analog	99
Ribociclib	Kinase inhibitor	131
Risperidone	Atypical antipsychotic	131
Rituxan	CD20-directed cytolytic antibody	95
Rituximab	CD20-directed cytolytic antibody	1,226
Rubraca	Poly(ADP-Ribose) polymerase inhibitor	136
Ruxolitinib	Janus kinase inhibitor	106
Selinexor	Nuclear export inhibitor	55
Sertraline	Serotonin reuptake inhibitor	63
Sintilimab		75
Sirolimus	Kinase inhibitor	127
Spironolactone	Aldosterone antagonist	56
Sulfasalazine	Aminosalicylate	87
Tacrolimus	Calcineurin inhibitor immunosuppressant	350
Talimogene laherparepvec		51
Temozolomide	Alkylating drug	187
Thalidomide		117
Topiramate		123
Topotecan	Topoisomerase inhibitor	59
Trametinib	Kinase inhibitor	66
Trastuzumab	HER2/neu receptor antagonist	277
Triamcinolone acetonide	Corticosteroid	103
Tylenol	Expectorant	60
Tyvaso	Prostacycline vasodilator	66
Tyvaso DPI	Prostacycline vasodilator	126
Valproate sodium	Anti-epileptic agent	54
Valproic acid	Anti-epileptic agent	101
Vectibix	Epidermal growth factor receptor antagonist	252
Vedolizumab	Integrin receptor antagonist	222
Velcade	Proteasome inhibitor	110
Venetoclax	BCL-2 inhibitor	81
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	57
Vincristine		632
Vincristine sulfate	Vinca alkaloid	121
Vinorelbine	Vinca alkaloid	59
Xgeva	RANK ligand inhibitor	73
Xolair	Anti-IgE	87
Zoledronic acid	Bisphosphonate	63

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 49 pharmacologic classes with 100 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Therapy partial responder name, in order of name
Class	Reports with this term
Alkylating drug	2,299
Amide local anesthetic	120
Aminosalicylate	135
Anthracycline topoisomerase inhibitor	852
Anti-epileptic agent	585
Anti-IgE	221
Antimalarial	202
Antimetabolite immunosuppressant	539
Antirheumatic agent	101
Aromatase inhibitor	196
Atypical antipsychotic	738
Benzodiazepine	326
Calcineurin inhibitor immunosuppressant	678
CD20-directed cytolytic antibody	1,405
CD38-directed cytolytic antibody	243
Corticosteroid	3,740
Epidermal growth factor receptor antagonist	509
Folate analog	115
Folate analog metabolic inhibitor	1,233
HER2/neu receptor antagonist	403
Human immunoglobulin G	100
Integrin receptor antagonist	304
Interleukin-17A antagonist	131
Interleukin-6 receptor antagonist	233
Janus kinase inhibitor	251
Kinase inhibitor	1,607
Leukocyte growth factor	249
Microtubule inhibitor	952
Mood stabilizer	120
Nonsteroidal anti-inflammatory drug	332
Nucleoside metabolic inhibitor	1,861
Opioid agonist	237
Phosphodiesterase 4 inhibitor	209
Platinum-based drug	2,571
Poly(ADP-Ribose) polymerase inhibitor	168
Programmed death Receptor-1 blocking antibody	2,007
Prostacycline vasodilator	467
Proteasome inhibitor	1,158
Purine antimetabolite	233
RANK ligand inhibitor	160
Serotonin and norepinephrine reuptake inhibitor	124
Serotonin reuptake inhibitor	215
Serotonin-1b and Serotonin-1d receptor agonist	133
Tetracycline-class drug	104
Thalidomide analog	729
Topoisomerase inhibitor	827
Tumor necrosis factor blocker	679
Vascular endothelial growth factor inhibitor	898
Vinca alkaloid	180

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Therapy partial responder, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Therapy partial responder
Age	Reports	Share
Under 2	110	0.7%
2 to 11	388	2.6%
12 to 17	341	2.3%
18 to 44	2,197	14.8%
45 to 64	3,513	23.6%
65 to 74	2,077	14%
75 and over	1,082	7.3%
Age not given	5,156	34.7%

Sex of the patient in the reports that record Therapy partial responder
Sex	Reports	Share
Female	6,016	40.5%
Male	5,348	36%
Unknown or not given	3,500	23.5%

Age and sex are as the report gives them. 29.7% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Therapy partial responder: adverse event reports that record this term. https://reportedreactions.com/reaction/therapy-partial-responder/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Therapy partial responder mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page